MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Arbutus Biopharma Corp

Avatud

3.08 -2.53

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.08

Max

3.18

Põhinäitajad

By Trading Economics

Sissetulek

-12M

-25M

Müük

190K

1.8M

Kasumimarginaal

-1,390.363

Töötajad

44

EBITDA

-12M

-24M

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

31. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-21M

621M

Eelmine avamishind

5.61

Eelmine sulgemishind

3.08

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

Arbutus Biopharma Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. juuli 2025, 23:34 UTC

Omandamised, ülevõtmised, äriostud

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17. juuli 2025, 21:14 UTC

Omandamised, ülevõtmised, äriostud

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17. juuli 2025, 21:04 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17. juuli 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17. juuli 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17. juuli 2025, 22:47 UTC

Omandamised, ülevõtmised, äriostud

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17. juuli 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17. juuli 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17. juuli 2025, 22:43 UTC

Omandamised, ülevõtmised, äriostud

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17. juuli 2025, 22:43 UTC

Omandamised, ülevõtmised, äriostud

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17. juuli 2025, 22:40 UTC

Omandamised, ülevõtmised, äriostud

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17. juuli 2025, 22:40 UTC

Omandamised, ülevõtmised, äriostud

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17. juuli 2025, 22:30 UTC

Market Talk
Tulu

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17. juuli 2025, 22:20 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

17. juuli 2025, 22:20 UTC

Market Talk
Tulu

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17. juuli 2025, 22:04 UTC

Market Talk
Tulu

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17. juuli 2025, 22:03 UTC

Omandamised, ülevõtmised, äriostud

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17. juuli 2025, 21:58 UTC

Market Talk
Tulu

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17. juuli 2025, 21:57 UTC

Tulu

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17. juuli 2025, 21:47 UTC

Tulu

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17. juuli 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. juuli 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17. juuli 2025, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17. juuli 2025, 21:22 UTC

Omandamised, ülevõtmised, äriostud

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17. juuli 2025, 21:05 UTC

Tulu

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17. juuli 2025, 21:04 UTC

Omandamised, ülevõtmised, äriostud

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17. juuli 2025, 21:02 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17. juuli 2025, 20:59 UTC

Omandamised, ülevõtmised, äriostud

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17. juuli 2025, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

17. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Arbutus Biopharma Corp Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

0

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.255 / 3.365Toetus ja vastupanu

Lühikene perspektiiv

Weak Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.